http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/ News About Tech, Money and Innovation Mon, 23 Nov 2009 10:55:42 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-645220 VentureBeat » Life sciences briefing: Wednesday, Nov. 21, 2007 Wed, 21 Nov 2007 22:29:54 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-645220 [...] its expected per-share range at $27. As we noted earlier — see our previous coverage here and here — Reliant is kind of a mixed bag insofar as specialty pharma companies go. It yanked an [...] [...] its expected per-share range at $27. As we noted earlier — see our previous coverage here and here — Reliant is kind of a mixed bag insofar as specialty pharma companies go. It yanked an [...]

]]> http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-635714 VentureBeat » Life sciences briefing: Thursday, Nov. 15, 2007 Thu, 15 Nov 2007 19:55:34 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-635714 [...] the other hand, at least IPO investors won’t get the company confused with Reliant Pharmaceuticals [...] [...] the other hand, at least IPO investors won’t get the company confused with Reliant Pharmaceuticals [...]

]]> http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-633432 VentureBeat » EnteroMedics and its risky obesity device, the latest victims of the IPO haircut Wed, 14 Nov 2007 21:39:47 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-633432 [...] and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...] [...] and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...]

]]> http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-633446 VentureBeat » EnteroMedics and its risky obesity device, the latest victims of the IPO haircut Wed, 14 Nov 2007 21:39:47 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-633446 [...] and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...] [...] and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...]

]]> http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-606916 VentureBeat » Life sciences briefing: Wednesday, Oct. 31, 2007 Wed, 31 Oct 2007 17:07:59 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-606916 [...] IPO range — Dublin’s Merrion Pharmaceuticals, a specialty pharma we last checked in on over the weekend, sharply lowered its expected IPO range. The company, which had hoped to sell as many as 4.6 [...] [...] IPO range — Dublin’s Merrion Pharmaceuticals, a specialty pharma we last checked in on over the weekend, sharply lowered its expected IPO range. The company, which had hoped to sell as many as 4.6 [...]

]]> http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/comment-page-1/#comment-606930 VentureBeat » Life sciences briefing: Wednesday, Oct. 31, 2007 Wed, 31 Oct 2007 17:07:59 +0000 http://venturebeat.com/2007/10/28/ipo-roundup-bioheart-merrion-pharma-in-limbo-reliant-vs-reliant-road-shows-upcoming-offerings/#comment-606930 [...] IPO range — Dublin’s Merrion Pharmaceuticals, a specialty pharma we last checked in on over the weekend, sharply lowered its expected IPO range. The company, which had hoped to sell as many as 4.6 [...] [...] IPO range — Dublin’s Merrion Pharmaceuticals, a specialty pharma we last checked in on over the weekend, sharply lowered its expected IPO range. The company, which had hoped to sell as many as 4.6 [...]

]]>